nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoclopramide—Consciousness abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.136	0.187	CcSEcCtD
Metoclopramide—Function kidney decreased—Cyclosporine—focal segmental glomerulosclerosis	0.108	0.149	CcSEcCtD
Metoclopramide—Altered state of consciousness—Cyclosporine—focal segmental glomerulosclerosis	0.0512	0.0702	CcSEcCtD
Metoclopramide—Hepatotoxicity—Cyclosporine—focal segmental glomerulosclerosis	0.0306	0.042	CcSEcCtD
Metoclopramide—CYP11B2—ACE Inhibitor Pathway—AGTR2—focal segmental glomerulosclerosis	0.0285	0.105	CbGpPWpGaD
Metoclopramide—Amenorrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.0269	0.0369	CcSEcCtD
Metoclopramide—CYP11B2—ACE Inhibitor Pathway—ACE—focal segmental glomerulosclerosis	0.0244	0.0897	CbGpPWpGaD
Metoclopramide—Urinary incontinence—Cyclosporine—focal segmental glomerulosclerosis	0.0228	0.0313	CcSEcCtD
Metoclopramide—Fluid retention—Cyclosporine—focal segmental glomerulosclerosis	0.0224	0.0308	CcSEcCtD
Metoclopramide—CYP11B2—ACE Inhibitor Pathway—AGTR1—focal segmental glomerulosclerosis	0.0219	0.0809	CbGpPWpGaD
Metoclopramide—Gynaecomastia—Cyclosporine—focal segmental glomerulosclerosis	0.0211	0.029	CcSEcCtD
Metoclopramide—Visual disturbance—Cyclosporine—focal segmental glomerulosclerosis	0.0181	0.0248	CcSEcCtD
Metoclopramide—Renal impairment—Cyclosporine—focal segmental glomerulosclerosis	0.018	0.0247	CcSEcCtD
Metoclopramide—CYP11B2—ACE Inhibitor Pathway—AGT—focal segmental glomerulosclerosis	0.0154	0.0569	CbGpPWpGaD
Metoclopramide—Bronchospasm—Cyclosporine—focal segmental glomerulosclerosis	0.0146	0.02	CcSEcCtD
Metoclopramide—Pollakiuria—Cyclosporine—focal segmental glomerulosclerosis	0.0137	0.0188	CcSEcCtD
Metoclopramide—Depression—Cyclosporine—focal segmental glomerulosclerosis	0.0132	0.0181	CcSEcCtD
Metoclopramide—Jaundice—Cyclosporine—focal segmental glomerulosclerosis	0.0129	0.0177	CcSEcCtD
Metoclopramide—Visual impairment—Cyclosporine—focal segmental glomerulosclerosis	0.0114	0.0157	CcSEcCtD
Metoclopramide—Flushing—Cyclosporine—focal segmental glomerulosclerosis	0.011	0.0151	CcSEcCtD
Metoclopramide—Nervousness—Cyclosporine—focal segmental glomerulosclerosis	0.01	0.0138	CcSEcCtD
Metoclopramide—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.00993	0.0136	CcSEcCtD
Metoclopramide—Tremor—Cyclosporine—focal segmental glomerulosclerosis	0.00968	0.0133	CcSEcCtD
Metoclopramide—Agitation—Cyclosporine—focal segmental glomerulosclerosis	0.00949	0.013	CcSEcCtD
Metoclopramide—Angioedema—Cyclosporine—focal segmental glomerulosclerosis	0.00944	0.013	CcSEcCtD
Metoclopramide—Leukopenia—Cyclosporine—focal segmental glomerulosclerosis	0.00925	0.0127	CcSEcCtD
Metoclopramide—Convulsion—Cyclosporine—focal segmental glomerulosclerosis	0.00895	0.0123	CcSEcCtD
Metoclopramide—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.00892	0.0122	CcSEcCtD
Metoclopramide—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.00876	0.012	CcSEcCtD
Metoclopramide—Confusional state—Cyclosporine—focal segmental glomerulosclerosis	0.0085	0.0117	CcSEcCtD
Metoclopramide—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.00843	0.0116	CcSEcCtD
Metoclopramide—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.00762	0.0105	CcSEcCtD
Metoclopramide—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.00752	0.0103	CcSEcCtD
Metoclopramide—CYP11B2—ACE Inhibitor Pathway—TGFB1—focal segmental glomerulosclerosis	0.0075	0.0276	CbGpPWpGaD
Metoclopramide—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	0.00749	0.0103	CcSEcCtD
Metoclopramide—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.00727	0.00998	CcSEcCtD
Metoclopramide—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.00695	0.00954	CcSEcCtD
Metoclopramide—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.0067	0.00919	CcSEcCtD
Metoclopramide—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.00666	0.00915	CcSEcCtD
Metoclopramide—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.00621	0.00853	CcSEcCtD
Metoclopramide—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.00605	0.0083	CcSEcCtD
Metoclopramide—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00577	0.00792	CcSEcCtD
Metoclopramide—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.00557	0.00765	CcSEcCtD
Metoclopramide—CYP11B1—Corticotropin-releasing hormone—GNAQ—focal segmental glomerulosclerosis	0.00536	0.0197	CbGpPWpGaD
Metoclopramide—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.00532	0.0073	CcSEcCtD
Metoclopramide—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00531	0.00729	CcSEcCtD
Metoclopramide—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.00528	0.00725	CcSEcCtD
Metoclopramide—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.00501	0.00687	CcSEcCtD
Metoclopramide—HTR3A—Ion channel transport—TRPC6—focal segmental glomerulosclerosis	0.00463	0.0171	CbGpPWpGaD
Metoclopramide—CHRM1—Regulation of Actin Cytoskeleton—MYH10—focal segmental glomerulosclerosis	0.00438	0.0161	CbGpPWpGaD
Metoclopramide—HTR4—GPCRs, Class A Rhodopsin-like—AGTR2—focal segmental glomerulosclerosis	0.00433	0.016	CbGpPWpGaD
Metoclopramide—HTR4—Class A/1 (Rhodopsin-like receptors)—AGTR2—focal segmental glomerulosclerosis	0.00371	0.0137	CbGpPWpGaD
Metoclopramide—HTR4—GPCRs, Class A Rhodopsin-like—AGTR1—focal segmental glomerulosclerosis	0.00333	0.0123	CbGpPWpGaD
Metoclopramide—HTR4—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.00285	0.0105	CbGpPWpGaD
Metoclopramide—HTR4—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.00283	0.0104	CbGpPWpGaD
Metoclopramide—CYP2D6—Melatonin metabolism and effects—EDN1—focal segmental glomerulosclerosis	0.00265	0.00975	CbGpPWpGaD
Metoclopramide—HTR4—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.00242	0.00892	CbGpPWpGaD
Metoclopramide—HTR4—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.00217	0.00801	CbGpPWpGaD
Metoclopramide—HTR4—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.00201	0.0074	CbGpPWpGaD
Metoclopramide—HTR4—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	0.00184	0.00679	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	0.00178	0.00657	CbGpPWpGaD
Metoclopramide—DRD3—G alpha (i) signalling events—AGTR2—focal segmental glomerulosclerosis	0.0017	0.00628	CbGpPWpGaD
Metoclopramide—CYP11B1—Corticotropin-releasing hormone—TGFB1—focal segmental glomerulosclerosis	0.00167	0.00616	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—GNAQ—focal segmental glomerulosclerosis	0.00162	0.00598	CbGpPWpGaD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	0.00161	0.00593	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.00161	0.00592	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.0016	0.00589	CbGpPWpGaD
Metoclopramide—DRD3—GPCRs, Class A Rhodopsin-like—AGTR2—focal segmental glomerulosclerosis	0.00158	0.00583	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	0.00157	0.00578	CbGpPWpGaD
Metoclopramide—CHRM1—Calcium Regulation in the Cardiac Cell—GNAQ—focal segmental glomerulosclerosis	0.00155	0.00569	CbGpPWpGaD
Metoclopramide—CHRM1—G alpha (q) signalling events—TRPC6—focal segmental glomerulosclerosis	0.00154	0.00568	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	0.00154	0.00566	CbGpPWpGaD
Metoclopramide—HTR4—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	0.00153	0.00564	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.00151	0.00556	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.00146	0.00538	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.00145	0.00534	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	0.00144	0.0053	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.00139	0.00511	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—TRPC6—focal segmental glomerulosclerosis	0.00138	0.00508	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—AGTR2—focal segmental glomerulosclerosis	0.00136	0.00499	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	0.00135	0.00499	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.00134	0.00495	CbGpPWpGaD
Metoclopramide—DRD2—G alpha (i) signalling events—AGTR2—focal segmental glomerulosclerosis	0.0013	0.00481	CbGpPWpGaD
Metoclopramide—CHRM1—G alpha (q) signalling events—GNAQ—focal segmental glomerulosclerosis	0.00129	0.00475	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	0.00127	0.00466	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—GNAQ—focal segmental glomerulosclerosis	0.00124	0.00458	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.00123	0.00453	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.00122	0.00449	CbGpPWpGaD
Metoclopramide—DRD3—GPCRs, Class A Rhodopsin-like—AGTR1—focal segmental glomerulosclerosis	0.00122	0.00448	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—GNAQ—focal segmental glomerulosclerosis	0.00122	0.00448	CbGpPWpGaD
Metoclopramide—DRD2—GPCRs, Class A Rhodopsin-like—AGTR2—focal segmental glomerulosclerosis	0.00121	0.00446	CbGpPWpGaD
Metoclopramide—CHRM1—GPCRs, Class A Rhodopsin-like—AGTR2—focal segmental glomerulosclerosis	0.00118	0.00437	CbGpPWpGaD
Metoclopramide—CHRM1—G alpha (q) signalling events—AGTR1—focal segmental glomerulosclerosis	0.00118	0.00434	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.00117	0.00432	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—GNAQ—focal segmental glomerulosclerosis	0.00115	0.00425	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.00112	0.00411	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	0.00109	0.00401	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—focal segmental glomerulosclerosis	0.00105	0.00388	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.00104	0.00384	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.00104	0.00384	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—AGTR2—focal segmental glomerulosclerosis	0.00104	0.00382	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.00103	0.0038	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—AGTR2—focal segmental glomerulosclerosis	0.00102	0.00374	CbGpPWpGaD
Metoclopramide—CHRM1—G alpha (q) signalling events—EDN1—focal segmental glomerulosclerosis	0.000999	0.00368	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—NOS2—focal segmental glomerulosclerosis	0.000954	0.00352	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000946	0.00348	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	0.000938	0.00346	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	0.000931	0.00343	CbGpPWpGaD
Metoclopramide—DRD2—GPCRs, Class A Rhodopsin-like—AGTR1—focal segmental glomerulosclerosis	0.000931	0.00343	CbGpPWpGaD
Metoclopramide—DRD3—G alpha (i) signalling events—AGT—focal segmental glomerulosclerosis	0.000923	0.0034	CbGpPWpGaD
Metoclopramide—CHRM1—Regulation of Actin Cytoskeleton—FN1—focal segmental glomerulosclerosis	0.000919	0.00339	CbGpPWpGaD
Metoclopramide—CHRM1—GPCRs, Class A Rhodopsin-like—AGTR1—focal segmental glomerulosclerosis	0.000911	0.00336	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—focal segmental glomerulosclerosis	0.000894	0.00329	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.000884	0.00326	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	0.000877	0.00323	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	0.000864	0.00318	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000862	0.00318	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000857	0.00316	CbGpPWpGaD
Metoclopramide—CHRM1—G alpha (q) signalling events—AGT—focal segmental glomerulosclerosis	0.000829	0.00306	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—SERPINE1—focal segmental glomerulosclerosis	0.000804	0.00296	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	0.000802	0.00296	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.000798	0.00294	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—LIPC—focal segmental glomerulosclerosis	0.000794	0.00293	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.000794	0.00292	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.00079	0.00291	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	0.000785	0.00289	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.000781	0.00288	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.000773	0.00285	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	0.000751	0.00277	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—focal segmental glomerulosclerosis	0.000742	0.00273	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.000734	0.0027	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—NOS2—focal segmental glomerulosclerosis	0.00073	0.00269	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.00072	0.00265	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—NOS2—focal segmental glomerulosclerosis	0.000715	0.00263	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	0.000715	0.00263	CbGpPWpGaD
Metoclopramide—DRD2—G alpha (i) signalling events—AGT—focal segmental glomerulosclerosis	0.000706	0.0026	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—CTGF—focal segmental glomerulosclerosis	0.000699	0.00258	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—LIPC—focal segmental glomerulosclerosis	0.000685	0.00252	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.000676	0.00249	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	0.000673	0.00248	CbGpPWpGaD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	0.000665	0.00245	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.000662	0.00244	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.000659	0.00243	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—GNAQ—focal segmental glomerulosclerosis	0.000644	0.00237	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—LIPC—focal segmental glomerulosclerosis	0.00064	0.00236	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	0.000616	0.00227	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—SERPINE1—focal segmental glomerulosclerosis	0.000615	0.00227	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.000607	0.00224	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—CTGF—focal segmental glomerulosclerosis	0.000603	0.00222	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—SERPINE1—focal segmental glomerulosclerosis	0.000602	0.00222	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.000594	0.00219	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.000587	0.00216	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.000583	0.00215	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	0.000576	0.00212	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—CTGF—focal segmental glomerulosclerosis	0.000564	0.00208	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.000561	0.00207	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	0.000559	0.00206	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	0.000559	0.00206	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—GNAQ—focal segmental glomerulosclerosis	0.000555	0.00205	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000551	0.00203	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.000549	0.00202	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—LPL—focal segmental glomerulosclerosis	0.000542	0.002	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.000533	0.00196	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.00053	0.00195	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—GNAQ—focal segmental glomerulosclerosis	0.000519	0.00191	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	0.000515	0.0019	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	0.000513	0.00189	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.000507	0.00187	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	0.000504	0.00186	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.00049	0.00181	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—LPL—focal segmental glomerulosclerosis	0.000485	0.00179	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—AGT—focal segmental glomerulosclerosis	0.000464	0.00171	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.000449	0.00165	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.000449	0.00165	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.000446	0.00164	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.000445	0.00164	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.000439	0.00162	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.000437	0.00161	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—FN1—focal segmental glomerulosclerosis	0.000428	0.00158	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000428	0.00158	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	0.000427	0.00157	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000422	0.00155	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	0.000418	0.00154	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—LPL—focal segmental glomerulosclerosis	0.000418	0.00154	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—AGT—focal segmental glomerulosclerosis	0.000415	0.00153	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000413	0.00152	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.000408	0.0015	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.000407	0.0015	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.000405	0.00149	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.000399	0.00147	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.000397	0.00146	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—LPL—focal segmental glomerulosclerosis	0.000391	0.00144	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.000388	0.00143	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.00038	0.0014	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.000379	0.0014	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.000375	0.00138	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.000367	0.00135	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—AGT—focal segmental glomerulosclerosis	0.000357	0.00132	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	0.000357	0.00131	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000345	0.00127	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.000343	0.00126	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.000341	0.00126	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.000336	0.00124	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—AGT—focal segmental glomerulosclerosis	0.000334	0.00123	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.000334	0.00123	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000327	0.00121	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000321	0.00118	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—ALB—focal segmental glomerulosclerosis	0.000318	0.00117	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	0.000316	0.00116	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000315	0.00116	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000313	0.00115	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.000312	0.00115	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.000305	0.00112	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.000291	0.00107	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	0.000287	0.00106	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.000285	0.00105	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—ALB—focal segmental glomerulosclerosis	0.000274	0.00101	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	0.000273	0.00101	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000264	0.000974	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.000263	0.000969	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000259	0.000953	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—ALB—focal segmental glomerulosclerosis	0.000257	0.000945	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	0.000242	0.00089	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000241	0.000887	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.000241	0.000887	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000239	0.000882	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	0.000236	0.000871	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000236	0.000868	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000234	0.000863	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	0.000225	0.000829	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	0.000219	0.000808	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	0.000215	0.000791	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	0.000204	0.000752	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.000201	0.000742	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—LPL—focal segmental glomerulosclerosis	0.000198	0.000729	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.000197	0.000726	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	0.000187	0.000691	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.000184	0.000678	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.00018	0.000664	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—LIPC—focal segmental glomerulosclerosis	0.000173	0.000638	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AGT—focal segmental glomerulosclerosis	0.000169	0.000624	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—FN1—focal segmental glomerulosclerosis	0.000156	0.000576	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	0.000156	0.000575	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	0.000153	0.000563	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CTGF—focal segmental glomerulosclerosis	0.000152	0.000562	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—LPL—focal segmental glomerulosclerosis	0.000151	0.000558	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	0.000148	0.000546	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	0.000143	0.000528	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GNAQ—focal segmental glomerulosclerosis	0.00014	0.000517	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	0.00014	0.000517	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	0.00013	0.00048	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AGT—focal segmental glomerulosclerosis	0.00013	0.000477	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	0.000127	0.000467	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—FN1—focal segmental glomerulosclerosis	0.00012	0.000441	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	0.000117	0.000432	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—LPL—focal segmental glomerulosclerosis	0.000106	0.000389	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	9.97e-05	0.000367	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	9.96e-05	0.000367	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	9.75e-05	0.000359	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—AGT—focal segmental glomerulosclerosis	9.04e-05	0.000333	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	8.22e-05	0.000303	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	7.63e-05	0.000281	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	7.47e-05	0.000275	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ALB—focal segmental glomerulosclerosis	6.94e-05	0.000256	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	6.29e-05	0.000232	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	6.16e-05	0.000227	CbGpPWpGaD
